PL191631B1 - Mikrogranulki o kontrolowanym uwalnianiu do podawania doustnego, sposób ich wytwarzania, preparat farmaceutyczny je zawierający oraz ich zastosowanie - Google Patents
Mikrogranulki o kontrolowanym uwalnianiu do podawania doustnego, sposób ich wytwarzania, preparat farmaceutyczny je zawierający oraz ich zastosowanieInfo
- Publication number
- PL191631B1 PL191631B1 PL335107A PL33510798A PL191631B1 PL 191631 B1 PL191631 B1 PL 191631B1 PL 335107 A PL335107 A PL 335107A PL 33510798 A PL33510798 A PL 33510798A PL 191631 B1 PL191631 B1 PL 191631B1
- Authority
- PL
- Poland
- Prior art keywords
- cisplatin
- microgranules
- coating
- mixture
- eudragit
- Prior art date
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title description 17
- 229910052697 platinum Inorganic materials 0.000 title description 9
- 239000008187 granular material Substances 0.000 title description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract description 114
- 229960004316 cisplatin Drugs 0.000 claims abstract description 113
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 238000002360 preparation method Methods 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 25
- 238000013270 controlled release Methods 0.000 claims abstract description 17
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 7
- 239000012736 aqueous medium Substances 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 4
- 238000001959 radiotherapy Methods 0.000 claims abstract description 4
- 238000009096 combination chemotherapy Methods 0.000 claims abstract description 3
- 239000011248 coating agent Substances 0.000 claims description 46
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 39
- 238000000576 coating method Methods 0.000 claims description 27
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 26
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 25
- 239000004480 active ingredient Substances 0.000 claims description 21
- 239000011780 sodium chloride Substances 0.000 claims description 20
- 239000000454 talc Substances 0.000 claims description 18
- 229910052623 talc Inorganic materials 0.000 claims description 18
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 15
- 239000004531 microgranule Substances 0.000 claims description 15
- 239000001069 triethyl citrate Substances 0.000 claims description 15
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 15
- 235000013769 triethyl citrate Nutrition 0.000 claims description 15
- 229920000642 polymer Polymers 0.000 claims description 14
- 239000000725 suspension Substances 0.000 claims description 13
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 10
- 239000010410 layer Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- 108010006654 Bleomycin Proteins 0.000 claims description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical group FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- 229960001561 bleomycin Drugs 0.000 claims description 6
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 6
- 229960002949 fluorouracil Drugs 0.000 claims description 6
- 239000004014 plasticizer Substances 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 4
- 230000008021 deposition Effects 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
- 229960005420 etoposide Drugs 0.000 claims description 3
- 238000001033 granulometry Methods 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 229940068968 polysorbate 80 Drugs 0.000 claims description 3
- 239000011253 protective coating Substances 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- 229960003048 vinblastine Drugs 0.000 claims description 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 3
- ZPLQIPFOCGIIHV-UHFFFAOYSA-N Gimeracil Chemical compound OC1=CC(=O)C(Cl)=CN1 ZPLQIPFOCGIIHV-UHFFFAOYSA-N 0.000 claims description 2
- 238000011394 anticancer treatment Methods 0.000 claims description 2
- 229950009822 gimeracil Drugs 0.000 claims description 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 claims description 2
- 229960001674 tegafur Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 claims 1
- 229950000193 oteracil Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 9
- 239000013066 combination product Substances 0.000 abstract description 2
- 229940127555 combination product Drugs 0.000 abstract description 2
- 238000011319 anticancer therapy Methods 0.000 abstract 1
- 238000009499 grossing Methods 0.000 abstract 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 27
- 238000001990 intravenous administration Methods 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000008213 purified water Substances 0.000 description 12
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 9
- 241000282472 Canis lupus familiaris Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000013268 sustained release Methods 0.000 description 7
- 239000012730 sustained-release form Substances 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 206010029155 Nephropathy toxic Diseases 0.000 description 6
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 6
- 239000011325 microbead Substances 0.000 description 6
- 231100000417 nephrotoxicity Toxicity 0.000 description 6
- 230000007694 nephrotoxicity Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000013020 final formulation Substances 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 206010065553 Bone marrow failure Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920003141 Eudragit® S 100 Polymers 0.000 description 2
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940105442 cisplatin injection Drugs 0.000 description 1
- 208000034404 cisplatin toxicity Diseases 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 229920001688 coating polymer Polymers 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000010218 electron microscopic analysis Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 231100000268 induced nephrotoxicity Toxicity 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 150000003901 oxalic acid esters Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 235000018770 reduced food intake Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9701545A FR2759293B1 (fr) | 1997-02-11 | 1997-02-11 | Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie |
| PCT/FR1998/000251 WO1998034599A1 (fr) | 1997-02-11 | 1998-02-10 | Microgranules contenant du cisplatine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL335107A1 PL335107A1 (en) | 2000-04-10 |
| PL191631B1 true PL191631B1 (pl) | 2006-06-30 |
Family
ID=9503556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL335107A PL191631B1 (pl) | 1997-02-11 | 1998-02-10 | Mikrogranulki o kontrolowanym uwalnianiu do podawania doustnego, sposób ich wytwarzania, preparat farmaceutyczny je zawierający oraz ich zastosowanie |
Country Status (24)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050096304A1 (en) * | 1998-09-08 | 2005-05-05 | David White | Method of treating cancer using dithiocarbamate derivatives |
| FR2790668B1 (fr) * | 1999-03-12 | 2002-07-26 | D B F | Granules contenant une substance vegetale et leur procede de preparation |
| WO2000069414A2 (fr) * | 1999-05-17 | 2000-11-23 | D.B.F. | Granules contenant une substance vegetale et leur procede de preparation |
| CN1874764B (zh) * | 2003-10-10 | 2012-08-01 | 埃法尔姆公司 | 含有银杏提取物的持续释放微粒及其制备方法 |
| FR2861990B1 (fr) * | 2003-11-10 | 2006-02-10 | Nouveaux Produits Pharma | Comprimes faiblement doses a reseau de polymeres |
| BRPI0518286A2 (pt) * | 2004-11-18 | 2008-11-11 | Bristol Myers Squibb Co | microesfera com revestimento entÉrico contendo ixabepilona e sua preparaÇço |
| EP1832293A4 (en) * | 2004-12-10 | 2009-01-07 | Tmrc Co Ltd | MEANS FOR THE TREATMENT OF CANCER METASTAS AND CANNESMAS TREATMENT |
| US9107824B2 (en) | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
| FR2918566B1 (fr) | 2007-07-11 | 2009-10-09 | Pierre Fabre Medicament Sa | Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine. |
| FR2918567B1 (fr) * | 2007-07-11 | 2012-08-03 | Pf Medicament | Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine. |
| CA2699224C (en) * | 2007-09-21 | 2014-12-16 | Evonik Roehm Gmbh | Ph-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol |
| CA2699227C (en) * | 2007-09-21 | 2014-12-02 | Evonik Roehm Gmbh | Ph-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol |
| HUE034848T2 (en) * | 2008-01-10 | 2018-03-28 | Evonik Roehm Gmbh | Coated pharmaceutical or nutraceutical preparation with enhanced active substance release in the colon |
| MX2010007578A (es) * | 2008-01-10 | 2010-08-03 | Evonik Roehm Gmbh | Preparacion nutriceutica o farmaceutica revestida con una liberacion acelerada controlada de sustancia activa. |
| DK177529B1 (en) * | 2009-10-23 | 2013-09-08 | Bio Bedst Aps | Liposomes with improved storage stability |
| CA2688202C (en) * | 2009-12-11 | 2012-11-13 | Bj Services Company | Viscoelastic fluids containing hydroxyethyl cellulose |
| EP2371356B1 (en) * | 2010-03-12 | 2012-12-19 | Phoeme GmbH | Multi-particle pharmaceutical formulation for colon absorption |
| US8070047B1 (en) * | 2010-12-02 | 2011-12-06 | Rohm And Haas Electronic Materials Llc | Flux composition and method of soldering |
| DK2892524T3 (da) | 2012-09-04 | 2021-01-25 | Eleison Pharmaceuticals LLC | Forebyggelse af pulmonalt kræfttilbagefald med lipid-komplekseret cisplatin |
| JP6487534B2 (ja) | 2014-09-05 | 2019-03-20 | シンビオミックス セラピューティクス、エルエルシー | 細菌性膣炎の治療に使用するためのセクニダゾール |
| US10238688B2 (en) * | 2015-04-24 | 2019-03-26 | Genedia Biotech Co., Ltd. | Combination therapies for bladder cancer |
| US11253501B2 (en) | 2015-06-01 | 2022-02-22 | Lupin Inc. | Secnidazole formulations and use in treating bacterial vaginosis |
| EA201792512A1 (ru) | 2015-06-12 | 2018-06-29 | Вэксарт, Инк. | Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник |
| TWI795462B (zh) | 2017-11-17 | 2023-03-11 | 日商鹽野義製藥股份有限公司 | 光安定性及溶出性優異的醫藥製劑 |
| JP6590436B1 (ja) * | 2018-04-24 | 2019-10-16 | 塩野義製薬株式会社 | 安定性に優れた固形製剤 |
| BR112020021059B1 (pt) * | 2018-04-24 | 2022-08-30 | Shionogi & Co., Ltd | Forma de dosagem sólida |
| US12280037B2 (en) | 2020-09-22 | 2025-04-22 | Evofem Biosciences, Inc. | Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0059817B1 (fr) * | 1981-03-11 | 1985-10-09 | Mirko Beljanski | Serpentine; alstonine et sempervirine, médicaments inhibant spécifiquement les cellules cancéreuses et tumorales |
| IT1153974B (it) * | 1982-09-23 | 1987-01-21 | Erba Farmitalia | Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento |
| DE3421468A1 (de) * | 1984-06-08 | 1985-12-19 | Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim | Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung |
| DE3523454A1 (de) * | 1985-07-01 | 1987-01-08 | Eberhard Prof Dr Nuernberg | Formkoerper |
| US4925674A (en) * | 1988-08-25 | 1990-05-15 | Himedics, Inc. | Amoxicillin microencapsulated granules |
| US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| JPH05294839A (ja) * | 1992-04-20 | 1993-11-09 | Biomaterial Universe Kk | シスプラチン含有生体内分解吸収性高分子の微小球お よびその製造法 |
| US5795882A (en) * | 1992-06-22 | 1998-08-18 | Bone Care International, Inc. | Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations |
| JPH07112932A (ja) * | 1993-08-27 | 1995-05-02 | Mitsui Toatsu Chem Inc | 徐放性医薬製剤 |
| JPH0789849A (ja) * | 1993-09-20 | 1995-04-04 | Fujisawa Pharmaceut Co Ltd | 徐放性製剤 |
| JPH0859460A (ja) * | 1994-08-22 | 1996-03-05 | Tanaka Kikinzoku Kogyo Kk | 抗ガン剤内包キトサンミクロスフェア及びその製造法 |
| US5637319A (en) * | 1995-03-01 | 1997-06-10 | Takada; Kanji | Controlled-release preparations |
| US5614206A (en) * | 1995-03-07 | 1997-03-25 | Wright Medical Technology, Inc. | Controlled dissolution pellet containing calcium sulfate |
| AU714992B2 (en) * | 1996-08-23 | 2000-01-13 | Alza Corporation | Liposomes containing a cisplatin compound |
-
1997
- 1997-02-11 FR FR9701545A patent/FR2759293B1/fr not_active Expired - Lifetime
-
1998
- 1998-02-10 WO PCT/FR1998/000251 patent/WO1998034599A1/fr active IP Right Grant
- 1998-02-10 NZ NZ337216A patent/NZ337216A/xx not_active IP Right Cessation
- 1998-02-10 PL PL335107A patent/PL191631B1/pl not_active IP Right Cessation
- 1998-02-10 DE DE69820239T patent/DE69820239T2/de not_active Expired - Lifetime
- 1998-02-10 IN IN337DE1998 patent/IN187998B/en unknown
- 1998-02-10 DK DK98908157T patent/DK0971702T3/da active
- 1998-02-10 TW TW087101722A patent/TW561055B/zh not_active IP Right Cessation
- 1998-02-10 JP JP53389798A patent/JP4549445B2/ja not_active Expired - Lifetime
- 1998-02-10 IL IL13132698A patent/IL131326A/xx not_active IP Right Cessation
- 1998-02-10 AT AT98908157T patent/ATE255409T1/de active
- 1998-02-10 BR BR9807319-2A patent/BR9807319A/pt not_active Application Discontinuation
- 1998-02-10 US US09/367,270 patent/US6458389B1/en not_active Expired - Lifetime
- 1998-02-10 KR KR10-1999-7007263A patent/KR100471672B1/ko not_active Expired - Fee Related
- 1998-02-10 CA CA002282082A patent/CA2282082C/fr not_active Expired - Lifetime
- 1998-02-10 HU HU0001719A patent/HU225425B1/hu not_active IP Right Cessation
- 1998-02-10 ES ES98908157T patent/ES2210726T3/es not_active Expired - Lifetime
- 1998-02-10 EP EP98908157A patent/EP0971702B1/fr not_active Expired - Lifetime
- 1998-02-10 EA EA199900734A patent/EA001760B1/ru not_active IP Right Cessation
- 1998-02-10 PT PT98908157T patent/PT971702E/pt unknown
- 1998-02-11 AR ARP980100613A patent/AR011133A1/es active IP Right Grant
- 1998-02-11 ZA ZA981123A patent/ZA981123B/xx unknown
-
1999
- 1999-08-10 BG BG103647A patent/BG64247B1/bg unknown
- 1999-08-11 NO NO19993881A patent/NO323230B1/no not_active IP Right Cessation
-
2002
- 2002-07-25 US US10/200,998 patent/US20030017210A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL191631B1 (pl) | Mikrogranulki o kontrolowanym uwalnianiu do podawania doustnego, sposób ich wytwarzania, preparat farmaceutyczny je zawierający oraz ich zastosowanie | |
| EP0711152B1 (en) | Powder-layered oral dosage forms | |
| US6077533A (en) | Powder-layered oral dosage forms | |
| EP0660705B1 (en) | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine | |
| US6066339A (en) | Oral morphine multiparticulate formulation | |
| CS268819B2 (en) | Method of particles production with effective substance's controlled loosening | |
| KR20100126465A (ko) | 미코페놀레이트를 포함하는 변형 방출 제약 조성물 및 그것의 방법 | |
| CZ5097A3 (en) | Pharmaceutical dosing form with controlled release, suitable for moguistein administration, process of its preparation and pharmaceutical composition | |
| PT88099B (pt) | Processo para a preparacao de composicoes farmaceuticas de acetaminofeno orais e de libertacao prolongada | |
| KR20100129756A (ko) | 약 염기성 약물 및 유기산을 포함하는 약물 전달 시스템 | |
| WO2009047799A1 (en) | High dose solid unit oral pharmaceutical dosage form of mycophenolate sodium and process for making same | |
| EP2187872A1 (en) | Extended release compositions comprising mycophenolate sodium and processes thereof | |
| HK1045107B (zh) | 吗啡硫酸盐微粒，其制备方法及含有此物质的成份 | |
| EP3052130B1 (en) | Pharmaceutical composition comprising capecitabine and cyclophosphamide | |
| EP4331569A1 (en) | Sorafenib or donafenib oral preparation with low dose and high drug exposure, and application thereof | |
| KR100714058B1 (ko) | 톨테로딘 엘-주석산염의 서방형 경구투여 조성물 및 이의 제조 방법 | |
| MXPA99007393A (en) | Microgranules containing cisplatin | |
| CA2558783C (en) | Oral morphine multiparticulate formulation | |
| KR100587165B1 (ko) | 알렌드로네이트 연질캡슐제제 | |
| WO2024218722A2 (en) | Compositions and methods for the treatment of coenzyme q10 deficiency | |
| Demina et al. | Modern Technologies for the Creation of Controlled Release Preparations of Isosorbide Dinitrate and Acylated Phenothiazine Derivatives for Peroral Administration (A Review). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RECP | Rectifications of patent specification | ||
| LAPS | Decisions on the lapse of the protection rights |
Effective date: 20120210 |